Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 3Terminated 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

NSCLC 2Breast Neoplasms 2Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma of Lung 1

Interventions

Trastuzumab 78Capecitabine 59Cyclophosphamide 54Paclitaxel 52Docetaxel 50Letrozole 44Fulvestrant 43Lapatinib 34Doxorubicin 31Carboplatin 31Vinorelbine 30Bevacizumab 29Anastrozole 28pembrolizumab 26exemestane 24Tamoxifen 23Gemcitabine 22Radiotherapy 21Albumin-Bound Paclitaxel 19Taxes 17Everolimus 17Epirubicin 15pertuzumab 13Ado-Trastuzumab Emtansine 13130-nm albumin-bound paclitaxel 13palbociclib 12Magnetic Resonance Spectroscopy 12liposomal doxorubicin 11atezolizumab 11Filgrastim 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Breast Neoplasms × HM781-36B × Clear all
NCT03744715 2024-03-05

A Study to Allow Continued Dosing and/or Follow-up of Patients Who Have Had Previous Exposure to Poziotinib

Spectrum Pharmaceuticals, Inc

Phase 2 Terminated
7 enrolled
Breast

Breast Neoplasms

NCT03429101 2021-01-15

A Study of Poziotinib in Combination With T-DM1 in HER2-Positive Breast Cancer

Spectrum Pharmaceuticals, Inc

Phase 1 Terminated
6 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡